# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ronald Reagan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML008-SYN-TD
- Date: 2001-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellison, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month post-fracture, dementia, and caregiver review. **S**

## History of present illness

Mr. Reagan returns six months after the repair of his right hip fracture. He has had no falls. Home physical therapy finished last month, and he keeps up the home exercise program with supervision. He walks in the house and garden every day with the walker. He had no aches or fever after the zoledronic acid infusion three months ago. The evening restlessness is mild and unchanged. Weekly respite, the home health aide, and caregiver education continue, and the caregiver burden score has fallen. **S**

| Element | Detail |
|---|---|
| Interval change | Home therapy finished; daily walks with the walker; home exercise program |
| Falls | None since the fracture |
| Infusion tolerance | No flu-like reaction after zoledronic acid |
| Behavior | Mild evening restlessness, unchanged |
| Function | Barthel Index 85; Timed Up and Go 16 seconds |
| Caregiver | Zarit Burden Interview 27 of 88, down from 41 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; appetite good; no fever |
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Musculoskeletal | Negative | No hip, thigh, or back pain |
| Neurological | Positive | Known memory loss, unchanged by his caregivers' account |
| Psychiatric | Positive | Mild evening restlessness; no low mood; GDS-15 score 3 |

5 systems reviewed. **S**

## Current medications

- Donepezil 10 mg oral tablet, one tablet by mouth daily in the morning **S**
- Cholecalciferol 50 mcg (2,000 units) oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/70 mmHg; pulse 64 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 78 kg; BMI 22.8 kg/m². All vital signs are synthetic.

Calcium: 9.4 mg/dL; Hemoglobin: 13.7 g/dL; Barthel Index: 85; GDS-15: 3. All results are synthetic.

## Change since baseline

- Calcium: 9 mg/dL at baseline, 9.4 mg/dL at this visit **S**
- Hemoglobin: 11.1 g/dL (low) at baseline, 13.7 g/dL at this visit **S**
- Barthel Index: 55 at baseline, 85 at this visit **S**
- GDS-15: 4 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, cheerful, and sociable |
| Cardiovascular | Regular rhythm at 64 per minute; no edema; no fall in blood pressure on standing |
| Musculoskeletal | Right hip incision well healed; painless hip movement; Timed Up and Go 16 seconds with the walker, down from 24 at the first visit |
| Neurological | Oriented to person, not to date; no focal weakness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Osteoporosis with right hip fragility fracture, healed** (M80.051D). Clinically healed, with no pain. Calcium 9.4 mg/dL after the first zoledronic acid infusion, which he tolerated without a reaction. **S**
   - Continue cholecalciferol 2,000 units daily and calcium from food.
   - Calcium, phosphorus, and kidney function before the second infusion in about nine months.
   - Vertebral fracture assessment and FRAX with the next DXA.
2. **History of falling** (Z91.81). No falls through six months; Timed Up and Go 16 seconds, improved from 24 but above the 12-second threshold, so fall risk remains increased. **S**
   - Continue the home exercise program, the walker, and supervision on stairs and at night.
3. **Dementia due to Alzheimer's disease, moderate (FAST stage 5)** (F02.B0). Stable, with mild evening restlessness that responds to routine. GDS-15 score 3. Barthel Index 85, the best since the fracture. **S**
   - Continue donepezil 10 mg each morning.
   - Yearly dementia review with MoCA, FAST stage, and ADL and IADL scores in about seven months.
4. **Caregiver support**. Zarit Burden Interview 27 of 88, down from 41 at the first visit, with weekly respite, the home health aide, and caregiver education. **S**
   - Continue respite and the aide.
   - Zarit Burden Interview again at the yearly review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum calcium after the first zoledronic acid infusion | Before each dose; checked once after the first | Completed today | 9.4 mg/dL; no low calcium after the infusion |
| Laboratory | Hemoglobin | Follow-up of postoperative anemia | Completed today | 13.7 g/dL; anemia resolved |
| Laboratory | Calcium, phosphorus, and kidney function before the second infusion | Before each intravenous dose | Due | In about nine months; phosphorus added after the gap noted at three months |
| Laboratory | 25-hydroxyvitamin D | Yearly after repletion | Up to date | 36 ng/mL three months ago; next in about nine months |
| Imaging | DXA | Every 1 to 3 years on therapy | Up to date | Baseline three months ago |
| Imaging | Vertebral fracture assessment | At baseline after a low-trauma fracture or with a T-score of -2.5 or lower | Due | Missed at the three-month DXA. Height still 185 cm and no back pain; planned with the next DXA |
| Examination | Timed Up and Go | When home therapy ends, then yearly or with a change | Completed today | 16 seconds with the walker, down from 24; above the 12-second threshold |
| Examination | CDC STEADI fall-risk screen: fall history, gait and balance, postural blood pressure | Every primary care visit after the fracture | Completed today | No falls; no fall in blood pressure on standing |
| Examination | Pain assessment | Every visit | Completed today | No pain |
| Examination | Physical and occupational therapy progress | Every visit | Completed today | Barthel Index 85; home therapy finished; home exercise program continues |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Completed today | Home safety changes in place; supervision at night |
| Medication safety | AGS Beers Criteria medication review | Every visit and at each transition of care | Completed today | Donepezil and cholecalciferol only; no Beers-listed medicine |
| Medication safety | Cholinesterase inhibitor benefit and tolerability | Each follow-up | Completed today | Heart rate 64; no fainting; continue |
| Medication safety | Zoledronic acid tolerance | After each infusion | Completed today | No acute-phase reaction; no thigh pain |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild evening restlessness, unchanged |
| Survey | Depression screen (GDS-15) | At 1, 3, and 6 months after the fracture; yearly in dementia | Completed today | Score 3, below the threshold of 5 |
| Survey | Caregiver assessment with the Zarit Burden Interview | At diagnosis, then every 6 to 12 months | Completed today | 27 of 88, down from 41 |
| Survey | Cognitive test (MoCA), FAST stage, and ADL and IADL scores | At diagnosis, then yearly | Up to date | Next at the yearly dementia review in about seven months |
| Survey | FRAX 10-year fracture risk | After the fracture and with each DXA | Due | Not calculated at the three-month DXA; planned with the next DXA |
| Referral | Caregiver support services | Ongoing | Completed today | Weekly respite, home health aide, and caregiver education continue |
| Self-management | Exercise program | Ongoing | Completed today | Home exercise program and daily supervised walks |
| Self-management | Advance care planning | At diagnosis, yearly, and at stage changes | Up to date | POLST completed three months ago; revisit at any change in stage |
| Self-management | Calcium intake from food and supplements | Ongoing; target 1,000 to 1,200 mg a day | Completed today | Calcium-rich food at each meal |

## Goal progress

- Walk household distances with a walker and supervision, with a Barthel Index of 75 or more, by the three-month visit. Outcome by 2001-04-14: Barthel Index rose from 55 to 75; walks in the house and garden with a walker. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more by three months, then the first zoledronic acid infusion. Outcome by 2001-04-14: 25-hydroxyvitamin D 36 ng/mL; zoledronic acid given. **S**
- No further falls through the six-month visit. Outcome by 2001-07-14: No falls; Timed Up and Go improved from 24 to 16 seconds. **S**
- Lower the spouse's Zarit Burden Interview score by at least 10 points by six months. Outcome by 2001-07-14: Zarit score fell from 41 to 27 with weekly respite, a home health aide, and caregiver education. **S**
- Document a health care agent, goals of care, and a POLST form by the three-month visit. Outcome by 2001-04-14: Health care agent confirmed and POLST completed with the patient and spouse. **S**

## Guideline basis

- Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline (2021), American Academy of Orthopaedic Surgeons
- The clinician's guide to prevention and treatment of osteoporosis (2022), Bone Health and Osteoporosis Foundation (Osteoporosis International)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD) (2024), Alzheimer's Association
- CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, hip/pelvic fracture, and osteoporosis monographs (2026), Aether Forge
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force

## Follow-up

- Annual wellness visit in three months. Yearly dementia review in about seven months. Calcium, phosphorus, and kidney function before the second zoledronic acid infusion in about nine months. **S**
- Next scheduled visit 2001-10-13: subsequent annual wellness visit. **S**
